Volume 11, Issue 2 (2025)
IEM 2025, 11(2): 179-188 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghelighi-Ghojogh M, Saberi A H, Amirkhanlou S. Investigating the Effect of Hemoperfusion Therapy on Laboratory and Clinical Factors in COVID-19 Patients: A Cross-Sectional Study. IEM 2025; 11 (2) :179-188
URL: http://iem.modares.ac.ir/article-4-78706-en.html
URL: http://iem.modares.ac.ir/article-4-78706-en.html
1- Neonatal and Children’s Research Center, Department of Biostatistics and Epidemiology, School of Health, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran
2- Medical Doctor, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Internal Medicine, Clinical Research Development Unit (CRDU), Shahid Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran ,Amirkhanloo@goums.ac.ir
2- Medical Doctor, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Internal Medicine, Clinical Research Development Unit (CRDU), Shahid Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran ,
Abstract: (669 Views)
Background: With the epidemic of the emerging COVID-19 disease in the world in 2019 and the lack of a definitive and effective treatment for it, medical science practically faced a new challenge, this study aimed to investigation the effect of hemoperfusion therapy on laboratory and clinical factors in COVID-19 patients.
Materials & Methods: In this cross-sectional study, 49 patients with severe COVID-19, who had indications for hemoperfusion were examined in 2020-2021. The patients underwent four hemoperfusion sessions after inserting a vascular catheter and preparing a special filter. Changes in laboratory and clinical factors before and after each hemoperfusion session were carefully recorded, and the data were analyzed using SPSS software.
Findings: The results of the study showed that the average age of the patients was 55.5 ± 13.9 years. Changes in the patients’ blood oxygen saturation levels after each hemoperfusion session showed a statistically significant improvement trend, the average values before and after the first session were 86.7±7.2% and 88.5±5.7%, respectively, indicating a significant increase (p= .009). Also, the inflammatory factor CRP (C-reactive protein) and blood platelet levels were significantly reduced after each hemoperfusion session.
Conclusion: This study showed that hemoperfusion could improve patients’ blood oxygen saturation values without causing any special complications and could also have a clear effect on clearing inflammatory factors and CRP from the blood.
Materials & Methods: In this cross-sectional study, 49 patients with severe COVID-19, who had indications for hemoperfusion were examined in 2020-2021. The patients underwent four hemoperfusion sessions after inserting a vascular catheter and preparing a special filter. Changes in laboratory and clinical factors before and after each hemoperfusion session were carefully recorded, and the data were analyzed using SPSS software.
Findings: The results of the study showed that the average age of the patients was 55.5 ± 13.9 years. Changes in the patients’ blood oxygen saturation levels after each hemoperfusion session showed a statistically significant improvement trend, the average values before and after the first session were 86.7±7.2% and 88.5±5.7%, respectively, indicating a significant increase (p= .009). Also, the inflammatory factor CRP (C-reactive protein) and blood platelet levels were significantly reduced after each hemoperfusion session.
Conclusion: This study showed that hemoperfusion could improve patients’ blood oxygen saturation values without causing any special complications and could also have a clear effect on clearing inflammatory factors and CRP from the blood.
Article Type: Original Research |
Subject:
Virology
Received: 2024/12/29 | Accepted: 2025/04/4 | Published: 2025/04/21
Received: 2024/12/29 | Accepted: 2025/04/4 | Published: 2025/04/21
References
1. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology. 2021;19(3):141-54. [DOI:10.1038/s41579-020-00459-7] [PMID] []
2. Maxmen A. Divisive COVID 'lab leak'debate prompts dire warnings from researchers. Nature. 2021;594(7861):15-6. [DOI:10.1038/d41586-021-01383-3] [PMID]
3. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical rheumatology. 2020;39(7):2085-94. [DOI:10.1007/s10067-020-05190-5] [PMID] []
4. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. (https://wwwwhoint/publications-detail/labo ratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases- 20200117) World Health Organization (WHO) Retrieved 30 March 2020.
5. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Frontiers in immunology. 2020;11:1648. [DOI:10.3389/fimmu.2020.01648] [PMID] []
6. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity. 2020;109:102433. [DOI:10.1016/j.jaut.2020.102433] [PMID] []
7. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet infectious diseases. 2020;20(8):911-9. [DOI:10.1016/S1473-3099(20)30287-5] [PMID]
8. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS chemical neuroscience. 2020;11(7):995-8. [DOI:10.1021/acschemneuro.0c00122] [PMID]
9. Wang CC, Prather KA, Sznitman J, Jimenez JL, Lakdawala SS, Tufekci Z, et al. Airborne transmission of respiratory viruses. Science. 2021;373(6558):eabd9149. [DOI:10.1126/science.abd9149] [PMID] []
10. Ronco C, Piccinni P, Kellum J. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique. Endotoxemia and Endotoxin Shock. 2010;167:25-34. [DOI:10.1159/000315916] [PMID]
11. Ankawi G, Xie Y, Yang B, Xie Y, Xie P, Ronco C. What have we learned about the use of cytosorb adsorption columns? Blood purification. 2019;48(3):196-202. [DOI:10.1159/000500013] [PMID]
12. Ronco C, Navalesi P, Vincent JL. Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. The Lancet Respiratory Medicine. 2020;8(3):240-1. [DOI:10.1016/S2213-2600(20)30060-6] [PMID]
13. Park S, Islam M-I, Jeong J-H, Cho N-J, Song H-y, Lee E-Y, et al. Hemoperfusion leads to impairment in hemostasis and coagulation process in patients with acute pesticide intoxication. Scientific reports. 2019;9(1):13325. [DOI:10.1038/s41598-019-49738-1] [PMID] []
14. Organization WH. Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023. World Health Organization, 2023.
15. Mathew G, Agha R, Albrecht J, Goel P, Mukherjee I, Pai P, et al. Strocss 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. International Journal of Surgery Open. 2021;37:100430. [DOI:10.1016/j.ijso.2021.100430]
16. Alavi Darazam I, Kazempour M, Pourhoseingholi MA, Hatami F, Rabiei MM, Javandoust Gharehbagh F, et al. Efficacy of hemoperfusion in severe and critical cases of COVID-19. Blood purification. 2023;52(1):8-16. [DOI:10.1159/000524606] [PMID] []
17. Mikaeili H, Taghizadieh A, Nazemiyeh M, Rezaeifar P, Zununi Vahed S, Safiri S, et al. The early start of hemoperfusion decreases the mortality rate among severe COVID‐19 patients: A preliminary study. Hemodialysis International. 2022;26(2):176-82. [DOI:10.1111/hdi.12982] [PMID]
18. Gómez-Rial J, Rivero-Calle I, Salas A, Martinon-Torres F. Role of monocytes/macrophages in Covid-19 pathogenesis: implications for therapy. Infection and Drug Resistance. 2020:2485-93. [DOI:10.2147/IDR.S258639] [PMID] []
19. Zhao Z, Wei Y, Tao C. An enlightening role for cytokine storm in coronavirus infection. Clinical Immunology. 2021;222:108615. [DOI:10.1016/j.clim.2020.108615] [PMID] []
20. Liang T, Cai H, Chen Y. Handbook of COVID-19 prevention and treatment: The First Affiliated Hospital, Zhejiang University School of Medicine, complied according to clinical experience: First Affiliated Hospital, Zhejiang University School of Medicine; 2020.
21. Abbasi S, Naderi Z, Amra B, Atapour A, Dadkhahi SA, Eslami MJ, et al. Hemoperfusion in patients with severe COVID-19 respiratory failure, lifesaving or not? Journal of Research in Medical Sciences. 2021;26(1):34. [DOI:10.4103/jrms.JRMS_1122_20] [PMID] []
22. Asgharpour M, Mehdinezhad H, Bayani M, Zavareh MSH, Hamidi SH, Akbari R, et al. Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19). BMC nephrology. 2020;21:1-10. [DOI:10.1186/s12882-020-02020-3] [PMID] []
23. Najafi A, Ahmadi A, Mojtahed-Zadeh M, Zarrin N, Moharari RS, Khajavi MR, et al. Evaluation of the Role of Hemoperfusion on Mortality and Morbidity in Patients with Severe Coronavirus Disease 2019 (COVID-19). Archives of Anesthesia and Critical Care. 2023. [DOI:10.18502/aacc.v9i3.13120]
24. Surasit K, Srisawat N. The efficacy of early additional hemoperfusion therapy for severe COVID-19 patients: A prospective cohort study. Blood purification. 2022;51(11):879-88. [DOI:10.1159/000521713] [PMID] []
25. Peng J-Y, Li L, Zhao X, Ding F, Hou X, Peng Z. Hemoperfusion with CytoSorb® in critically ill COVID-19 patients. Blood purification. 2022;51(5):410-6. [DOI:10.1159/000517721] [PMID] []
26. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama. 2020;323(13):1239-42. [DOI:10.1001/jama.2020.2648] [PMID]
27. Siasat A, Ilagan B, Reyes A, Ronquillo R, Clemente C, Chan A, et al. POS-875 THE CLINICAL PROFILE AND OUTCOME OF PATIENTS WITH COVID 19 WHO UNDERWENT HEMOPERFUSION IN BATAAN GENERAL HOSPITAL AND MEDICAL CENTER. Kidney International Reports. 2022;7(2):S378-S9. [DOI:10.1016/j.ekir.2022.01.913] []
28. Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virology journal. 2022;19(1):92. [DOI:10.1186/s12985-022-01814-1] [PMID] []
29. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International journal of antimicrobial agents. 2020;55(5):105954. [DOI:10.1016/j.ijantimicag.2020.105954] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |